Validating Novo Nordisk’s decision to research the cardiovascular impact of Wegovy (semaglutide), US authorities have said Medicare patients with heart problems 22 March 2024
Just a couple of months after launching its direct-to-consumer pharmacy service, Eli Lilly (NYSE: LLY) has announced plans to ramp things up significantly. 14 March 2024
Following discussions with the US regulator, Texan drugmaker Lexicon Pharmaceuticals now plans to resubmit a New Drug Application (NDA) for sotagliflozin. 12 March 2024
Novo Nordisk’s (NOV: N) investments in GLP-1 agonism and related approaches to weight loss are continuing to bear fruit, as shown by striking headline data from 8 March 2024
In another legal blow for opponents of the Inflation Reduction Act (IRA), a federal judge has now rejected a bid from AstraZeneca to prevent price negotiations 4 March 2024
Germany’s Boehringer Ingelheim has announced positive results from a Phase II trial of survodutide, a glucagon/GLP-1 receptor dual agonist. 26 February 2024
Industry observers are cautiously hoping that early 2024 signs indicate that the post-pandemic biotech fundraising slowdown might be coming to and end. 30 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.